{"filing":{"accession_number":"0001193125-26-274093","cik":"0001800315","ticker":"DMRA","company_name":"Damora Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-17","report_date":null,"primary_document":"dmra-20260428.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1800315/000119312526274093/dmra-20260428.htm"},"events":[{"id":11505,"run_id":10102,"accession_number":"0001193125-26-274093","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on four proposals at the 2026 Annual Meeting held June 17, 2026: election of two Class III directors (Michael Landsittel and Cameron Turtle), Say-on-Pay advisory vote, Say-on-Frequency advisory vote, and auditor ratification. All proposals passed with strong majorities, and the Board determined to hold annual Say-on-Pay votes based on the voting results.","company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","filing_date":"2026-06-17","submitted_at":null,"items":[{"id":8105,"accession_number":"0001193125-26-274093","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on four proposals at the 2026 Annual Meeting held June 17, 2026: election of two Class III directors (Michael Landsittel and Cameron Turtle), Say-on-Pay advisory vote, Say-on-Frequency advisory vote, and auditor ratification. All proposals passed with strong majorities, and the Board determined to hold annual Say-on-Pay votes based on the voting results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:01:05.770491+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":8105,"accession_number":"0001193125-26-274093","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder meeting results. The filing reports voting outcomes on four proposals at the 2026 Annual Meeting held June 17, 2026: election of two Class III directors (Michael Landsittel and Cameron Turtle), Say-on-Pay advisory vote, Say-on-Frequency advisory vote, and auditor ratification. All proposals passed with strong majorities, and the Board determined to hold annual Say-on-Pay votes based on the voting results.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-17T20:01:05.770491+00:00","company_name":"Damora Therapeutics, Inc.","ticker":"DMRA","filing_date":"2026-06-17"}]}